Hearing loss occurred more frequently among adults who received teprotumumab for the treatment of thyroid eye disease if they had impaired hearing at the start of therapy, according to a research letter published in Thyroid.
In a small prospective cohort study, one adult out of 32 (3%) with normal hearing at baseline developed hearing decline after a full, 24-week course of teprotumumab-trbw (Tepezza, Amgen). However, among 20 adults who had hearing dysfunction at baseline, 50% had a decline in hearing during teprotumumab treatment and four did not have a resolution (Read more...)